<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517149</url>
  </required_header>
  <id_info>
    <org_study_id>4D-125-C001</org_study_id>
    <nct_id>NCT04517149</nct_id>
  </id_info>
  <brief_title>4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)</brief_title>
  <official_title>An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4D Molecular Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4D Molecular Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2 multicenter study with two parallel parts: an observational natural&#xD;
      history cohort and an open-label, prospective interventional trial in males with&#xD;
      non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in retinitis pigmentosa&#xD;
      GTPase regulator (RPGR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1/2 study will gather data in an observational phase Natural History Cohort to&#xD;
      further characterize and evaluate natural disease progression in male patients with&#xD;
      genetically-confirmed X-linked retinitis pigmentosa (XLRP) caused by mutations in the gene&#xD;
      encoding retinitis pigmentosa GTPase regulator (RPGR). The study will also evaluate the&#xD;
      safety and tolerability, as assessed by frequency and severity of ocular and systemic adverse&#xD;
      events, as well as preliminary clinical efficacy of a single intravitreal (IVT) injection of&#xD;
      4D-125 at two dose levels in this patient population.&#xD;
&#xD;
      4D-125 has been developed as a gene replacement therapy for XLRP. After receiving 4D-125,&#xD;
      patients will be followed for 24 months with continued safety follow-up. Secondary endpoints&#xD;
      will assess preliminary efficacy measures at 12 months after 4D-125 administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In Phase 1, up to 2 dose exploration cohorts will be enrolled; each cohort will initially recruit up to 3 patients to receive a single uniocular IVT injection of 4D-125 in a standard 3+3 design. The cohort will be expanded in the event of a dose limiting toxicity (DLT). Any cohort may be expanded by an additional 3 subjects (to a maximum of 9 patients) to provide additional safety information and/or to confirm the selected dose for expansion. Once the dose level has been selected, the Phase 2 Dose Expansion Cohort will be opened to dose an additional 6-12 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measure</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parameters</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>4D-125 Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 and Dose 2&#xD;
4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4D-125 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Natural History</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4D-125 IVT Injection</intervention_name>
    <description>4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.</description>
    <arm_group_label>4D-125 Dose Expansion</arm_group_label>
    <arm_group_label>4D-125 Dose Exploration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Natural History</description>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Natural History Key Inclusion Criteria:&#xD;
&#xD;
          -  Male, ≥ 6 years of age at the time of informed consent&#xD;
&#xD;
          -  Hemizygous non-syndromic RPGR mutation confirmed by genetic testing&#xD;
&#xD;
        Interventional Key Inclusion Criteria:&#xD;
&#xD;
          -  Male, ≥18 years of age&#xD;
&#xD;
          -  Hemizygous non-syndromic RPGR mutation confirmed by genetic testing&#xD;
&#xD;
          -  Phase 1 Dose Exploration: At least one eye amenable to IVT injection and BCVA ≤ 78&#xD;
             ETDRS letters (~20/32) and ≥ 34 ETDRS letters (~20/200)&#xD;
&#xD;
          -  Phase 2 Dose Expansion: At least one eye amenable to IVT injection AND both eyes must&#xD;
             have BCVA ≥ 34 ETDRS letters (~20/200)&#xD;
&#xD;
        Key Exclusion Criteria (all cohorts)&#xD;
&#xD;
          -  Patient has previously received any AAV treatment&#xD;
&#xD;
          -  Pre-existing eye conditions or surgical complications that would preclude&#xD;
             participation in an interventional clinical trial or interfere with the interpretation&#xD;
             of study endpoints&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>4D Molecular Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivia Lam</last_name>
    <phone>510-902-2065</phone>
    <email>clinicaltrials@4DMT.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Preston</last_name>
      <email>Mary.Preston@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Mathias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wietholter</last_name>
      <email>scwoo@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Cagri Besirli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center/Dept. of Ophthalmology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol White, CCRC</last_name>
      <email>Carol.White302@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Alessandro Iannaccone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Pol</last_name>
      <email>Pol@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Yang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Klein</last_name>
      <email>MKlein@retinafoundation.org</email>
    </contact>
    <investigator>
      <last_name>David Birch, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah John A. Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Allman</last_name>
      <email>Susan.Allman@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Bernstein, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>June 12, 2021</last_update_submitted>
  <last_update_submitted_qc>June 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XLRP</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

